Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 2 de 2
1.
Sci Rep ; 14(1): 10053, 2024 05 02.
Article En | MEDLINE | ID: mdl-38698047

Type 2 diabetes mellitus is a worldwide public health issue. In the globe, Egypt has the ninth-highest incidence of diabetes. Due to its crucial role in preserving cellular homeostasis, the autophagy process has drawn a lot of attention in recent years, Therefore, the purpose of this study was to evaluate the traditional medication metformin with the novel therapeutic effects of cinnamondehyde on adipocyte and hepatic autophagy in a model of high-fat diet/streptozotocin-diabetic rats. The study was conducted on 40 male albino rats, classified into 2 main groups, the control group and the diabetic group, which was subdivided into 4 subgroups (8 rats each): untreated diabetic rats, diabetic rats received oral cinnamaldehyde 40 mg/kg/day, diabetic rats received oral metformin 200 mg/kg/day and diabetic rats received a combination of both cinnamaldehyde and metformin daily for 4 weeks. The outcomes demonstrated that cinnamaldehyde enhanced the lipid profile and glucose homeostasis. Moreover, Cinnamaldehyde had the opposite effects on autophagy in both tissues; by altering the expression of genes that control autophagy, such as miRNA 30a and mammalian target of rapamycin (mTOR), it reduced autophagy in adipocytes and stimulated it in hepatic tissues. It may be inferred that by increasing the treatment efficacy of metformin and lowering its side effects, cinnamaldehyde could be utilized as an adjuvant therapy with metformin for the treatment of type 2 diabetes.


Acrolein , Acrolein/analogs & derivatives , Adipocytes , Autophagy , Diabetes Mellitus, Experimental , Liver , Metformin , Animals , Acrolein/pharmacology , Acrolein/therapeutic use , Autophagy/drug effects , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Experimental/metabolism , Liver/drug effects , Liver/metabolism , Liver/pathology , Male , Rats , Adipocytes/drug effects , Adipocytes/metabolism , Metformin/pharmacology , Diet, High-Fat/adverse effects , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/metabolism , MicroRNAs/metabolism , MicroRNAs/genetics , Hypoglycemic Agents/pharmacology , Hypoglycemic Agents/therapeutic use , Streptozocin , Blood Glucose/metabolism , TOR Serine-Threonine Kinases/metabolism
2.
Pharmaceutics ; 14(10)2022 Oct 08.
Article En | MEDLINE | ID: mdl-36297569

BACKGROUND: Obesity is a pandemic disease that is rapidly growing into a serious health problem and has economic impact on healthcare systems. This bleak image has elicited creative responses, and nanotechnology is a promising approach in obesity treatment. This study aimed to investigate the anti-obesity effect of superparamagnetic iron oxide nanoparticles (SPIONs) on a high-fat-diet rat model of obesity and compared their effect to a traditional anti-obesity drug (orlistat). METHODS: The obese rats were treated daily with orlistat and/or SPIONs once per week for 8 weeks. At the end of the experiment, blood samples were collected for biochemical assays. Then, the animals were sacrificed to obtain white adipose tissues (WAT) and brown adipose tissues (BAT) for assessment of the expression of thermogenic genes and mitochondrial DNA copy number (mtDNA-CN). RESULTS: For the first time, we reported promising ameliorating effects of SPIONs treatments against weight gain, hyperglycemia, adiponectin, leptin, and dyslipidemia in obese rats. At the molecular level, surprisingly, SPIONs treatments markedly corrected the disturbed expression and protein content of inflammatory markers and parameters controlling mitochondrial biogenesis and functions in BAT and WAT. CONCLUSIONS: SPIONs have a powerful anti-obesity effect by acting as an inducer of WAT browning and activator of BAT functions.

...